Eurogin is part of the Informa Markets Division of Informa PLC

Informa
Informa

Early bird rates available! Secure your pass now!

  • How effective is HPV genotyping in screening?
    • J. Bonde (Denmark)
    • J. Dillner (Sweden)
  • Cervical cancer screening: Harms and benefit ratio in the changing world of cervical cancer screening
    • M. Rebolj (UK)
    • S. Van Dijk (Netherlands)
  • Screening for HPV-vaccinated cohorts: Country-specific experience
    • J. Lei (Sweden)
    • P. Sasieni (UK)
  • The utility of urine for improved cervical cancer prevention
    • R. Steenbergen (Netherlands)
    • A. Vorsters (Belgium)
  • Risk stratification in cervical cancer screening
    • H. Berkhof (Netherlands)
    • F. Inturrisi (Netherlands)
  • Self-sampling
    • G. Ogilvie (Canada)
    • M. Saville (Australia)
  • Self-sampling implementation
    • J. Bonde (Denmark)
    • M. Poljak (Slovenia)
  • What role of cytology in HPV screening: Are we really ready to abandon morphological data completely and use only virological data?
    • F. Carozzi (Italy)
  • RISCC: Implementation of risk-based cervical cancer screening in Europe
    • J. Berkhof (Netherlands)
    • M. Elfström (Sweden)
  • Gender-neutral vaccination: Impact on speed of elimination and subsequent need for screening
    • E. Franco (Canada)
    • M. Lehtinen (Finland)
  • One-dose vaccination: What do we know, what will we know and what are the remaining evidence gaps?
    • M. Brisson (Canada)
    • M. Jit (UK)
  • Vaccination hesitancy, recovery and public advocacy
    • S. Hanley (UK)
    • I. Olkov (France)
  • PERCH(PartnERship to Contrast HPV): an EU Joint Action aiming for improved HPV vaccination coverage and data collection
    • M. Arbyn (Belgium)
    • R. Bucciardini (Italy)
  • Scientific approaches to definition of HPV vaccine-induced protective immunity
    • S. Beddows (UK)
    • J. Dillner (Sweden)
    • M. Lehtinen (Finland)
  • Multi-sector partnerships to accelerate HPV vaccination: Real world evidence
    • M. Fisher-Borne (USA)
  • HPV type replacement
    • E. Franco (Canada)
  • Use of genotyping for management
    • F. Carozzi (Italy)
    • F. Inturrisi (Netherlands)
  • Persistent HPV without HSIL lesions in colposcopy
    • K. Louvanto (Finland)
  • Vaccination in women with CIN treatment
    • P. Nieminen (Finland)
    • B. Strander (Sweden)
  • HPV genital diseases during pregnancy
    • K. Louvanto (Finland)
    • E. Siegler (Israel)
  • Putting anal cancer screening into practice: Implementation science, biomarker development, and self-sampling
    • A. Burchell (Canada)
    • A. Nyitray (USA)
  • Implementation of anal cancer screening: Challenges and solutions
    • J. Palefsky (USA)
  • Research to advance prevention of cervical and HPV-related cancers among women living with HIV
    • A. Giuliano (USA)
    • V. Sahasrabuddhe (USA)
  • Sexual abuse and HPV
    • A. B. Moscicki (USA)
    • S. Syrjänen (Finland)
  • HPV driven cancer among people living with HIV
    • A. B. Moscicki (USA)
    • M. Muchengeti (South Africa)
  • Cervical cancer screening in LMICs
    • J. Smith (USA)
  • Screening for HPV-related cancer in sexual and gender minority adults
    • S. Jackson (USA)
    • A. Kreimer (USA)
  • HPV vaccination in vulnerable populations
    • M. Bardou (France)
    • I. Baussano (France)
  • Validation of HPV assays
    • M. Arbyn (Belgium)
    • M. Poljak (Slovenia)
  • Global overview of commercial HPV tests: 2024 status
    • K. Cuschieri (UK)
    • M. Poljak (Slovenia)
  • Methylation markers as management tool in anal, vulvar and cervical intraepithelial neoplasms
    • M. Bleeker (Netherlands)
    • M. Clarke (USA)
  • Indications for methylation testing in cervical screening and in the diagnosis of cervical and non-cervical HPV-associated lesions
    • D. Heideman (Netherlands)
    • R. Steenbergen (Netherlands)
  • Newest insights into oncogenesis
    • J. Doorbar (UK)
    • R. Steenbergen (Netherlands)
  • Present status of genome-wide association studies
    • P. Hillemanns (Germany)
  • Microbiome
    • C. Bouchard (Canada)
    • G. Ogilvie (Canada)
  • Newest insights into HPV epidemiology
    • S. Franceschi (Italy)
    • A. Kreimer (USA)
  • Challenges and implications of viral load and cellularity measurements
    • M. Arbyn (Belgium)
    • C. Cocuzza (Italy)
  • Global HPV laboratory network
    • S. Arroyo Mühr (Sweden)
    • K. Cuschieri (UK)
  • VALGENT/VALHUDES
    • M. Arbyn (Belgium)
    • D. Hawkes (Australia)
  • Debate session
    • E. Franco (Canada)
    • T. J. Palmer (UK)
  • Vulvar diseases
    • M. Bleeker (Netherlands)
    • M. Hampl (Germany)
  • Colposcopy course
    • J. Bornstein (Israel)
    • A. Singer (UK)

Coordinators: J. Bonde (Denmark) - J. Dillner (Sweden)

  • The Nordic session - Part 1
    Next level for HPV vaccine in the nordic countries
  • The Nordic Session - Part 2
    Next level for cervical screening in the nordic countries

Coordinators: C. Brenner (USA) - J. P. Klussmann (Germany) - K. Lang Kuhs (USA) - S. Virani (France)

  • Epidemiology and prevention of HPV-OPC
    • E. Rettig (USA)
  • Screening for HPV-OPC
    • K. Lang Kuhs (USA)
    • T. Waterboer (Germany)
  • Basic science
    • C. Brenner (USA)
    • S. Virani (France)
  • Management
    • J. P. Klussmann (Germany)
    • S. Puram (USA)
  • Molecular diagnosis and surveillance
    • C. J. Brenner (USA)
    • H. Mirghani (France)
  • Recurrent respiratory papillomatosis (RRP)
    • S. Best (USA)